FOXO1 or not FOXO1:that is the question  

作　　者：Maude Marchais Marianne Mangeney 

机构地区：[1]Viroxis,Gustave Roussy Institute,Villejuif,France [2]Physiology and Molecular Pathology of Endogenous and Infectious Retroviruses Unit,CNRS UMR 9196,Gustave Roussy Institute,Paris-Saclay University,Villejuif,France

出　　处：《Cancer Communications》2025年第1期43-45,共3页癌症通讯(英文)

基　　金：supported by INSERM,CNRS,La Ligue Nationale Contre le Cancer(RS20/75-99,Inserm Transfert[CoPOC MAT-PI-171185-A-01]);Bristol Myers Squibb Foundation for Research in Immuno-Oncology;Bristol-Myers Squibb,Grant/Award Number:260403;Ligue Contre le Cancer。

摘　　要：Two groundbreaking articles in Nature by Evan W.Weber[1]and Philippe Darcy teams[2]revealed that overexpressing the transcription factor Forkhead Box O1(FOXO1)boosts Chimeric Antigen Receptor-T(CAR-T)cell antitumor activity against various tumors,including solid ones.Paradoxically,we recently described that pharmacological inhibition of FOXO1 transcriptional activity by AS184856 treatment in resting T cells enables the generation of non-activated CAR-T cells that outperforms solid tumor eradication compared to ex vivo-activated CAR-T cells[3].Our findings confirm the interest in using non-activated CAR-T cells,echoing two other studies that achieved more potent CAR-T cells by transducing resting T cells cultured with interleukin 7(IL-7),with[4]or without[5]the addition of IL-15.

关 键 词：FOXO1 ANTIGEN WEBER 

分 类 号：R73[医药卫生—肿瘤]